Novel mechanisms regulating immunity to respiratory virus infection
调节呼吸道病毒感染免疫力的新机制
基本信息
- 批准号:10753849
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-02 至 2023-08-11
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Respiratory Distress SyndromeAddressAnti-Inflammatory AgentsAntiviral AgentsAntiviral ResponseB-LymphocytesBacterial InfectionsBacterial PneumoniaCD80 geneCell physiologyCellsCessation of lifeCytotoxic T-LymphocytesDataDiseaseEpidemicGranzymeHealthHumanHyperimmunoglobulin M SyndromeHypoxiaImmuneImmune responseImmunityIn VitroInfectionInflammationInfluenzaInfluenza A virusInterferon Type IIInterleukin-10Knockout MiceKnowledgeLigandsLungLymphocyteLymphocyte FunctionMalignant NeoplasmsMediatingMorbidity - disease rateMultiple Organ FailureMusMutateNatural Killer CellsOutcomePDL1 pathwayPathway interactionsPersonsPhenotypePopulationPublic HealthPulmonary PathologyRNA VirusesRag1 MouseRoleSeasonsSeverity of illnessSignal PathwaySignal TransductionSliceStructure of parenchyma of lungSuspensionsT cell regulationT-LymphocyteTherapeuticViralViral PneumoniaVirusVirus DiseasesVirus ReplicationWild Type MouseWorkantiviral immunitycell typechronic infectioncytokineexhaustionfightinghumoral immunity deficiencyimmune cell infiltrateimmunopathologyimmunoregulationimprovedinfluenza infectioninfluenzavirusinterleukin-10 receptormast cellmortalityneutralizing antibodynovelnovel therapeuticspandemic potentialpharmacologicpreventprogrammed cell death ligand 1programmed cell death protein 1respiratory infection virusresponsetherapeutic targettumorvaccination outcomeviral resistance
项目摘要
Influenza viruses are rapidly mutating RNA viruses and are the causative agent of about one billion annual
respiratory virus infections and 500,000 deaths worldwide. Influenza-related deaths are generally attributable to
viral or bacterial pneumonia (from secondary bacterial infections); excessive inflammation resulting in acute
respiratory distress syndrome; and severe lung immunopathology, leading to hypoxia and multi-organ failure.
Influenza viruses have significant pandemic potential, seasonal epidemics burden the human population, and
viral resistance has developed to all available treatment options. Much emphasis is placed on the humoral
immune response to influenza, as neutralizing antibodies are the desired vaccine outcome. However, B cell-
deficient mice and humans with hyper-IgM syndrome clear influenza virus infections, while T cell-deficient mice
do not. Thus, B cell-independent mechanisms protect against influenza virus-related mortality. However, the
immune response to influenza virus infection remains poorly understood, and much-needed therapeutics
augmenting the antiviral immune response while preventing harmful immunopathology remain to be developed.
To address this knowledge gap, we recently generated novel and compelling evidence that Influenza A virus
(IAV) infection triggers lung mast cells (MCs) to produce the anti-inflammatory cytokine IL-10 (MC-IL-10). In wild-
type (WT) and T- and B-cell deficient (Rag1-KO) mice, IAV/MC-IL-10 induces the expression of the IL-10 receptor
(IL-10R) and programmed cell death ligand 1 (PD-L1) on Natural Killer (NK) cells. Notably, in Rag1-KO mice,
where NK cells are the sole virus-fighting lymphocytes, PD-L1 blockade, but not PD-1, PD-L2, or CD80 blockade,
significantly reduces IAV-related lethality. The IAV/MC-IL10/NK-PD-L1 pathway is also conserved in humans, at
least in vitro: IAV infection of human-lung tissue-derived single-primary-cell suspensions or intact human lung
tissue slices elicit MC-IL-10 and NK cell-expressed IL-10R and PD-L1. In mice and humans, T cells also
upregulate the IL-10R, PD-1, and PD-L1 upon IAV infection. Further, IAV-infected IL-10-KO/Rag-WT mice,
whose NK and T cells do not upregulate IL-10R, PD-1, PD-L1, or PD-L2, and IAV-infected WT mice in which
PD-L1 is blocked, develop prolonged immune infiltration and immunopathology after IAV clearance. Our findings
are novel and surprising. The induction of the PD/PD-L pathway is generally associated with lymphocyte
exhaustion (via T cell-expressed PD-1) in cancer or chronic infection rather than the modulation of lymphocyte
function in response to an acute viral illness. We hypothesize that influenza virus-induced MC-IL-10 balances
helpful antiviral responses with harmful immunopathology through PDL1 signaling in NK cells, and PD-1 and/or
PD-L1 signaling in T cells. We propose identifying the mechanisms of IAV/MC/IL-10/PD-L1-mediated NK cell
and IAV/MC/IL-10/PD-1 and/or PD-L1-mediated T cell regulation and each pathway's contribution to viral
clearance vs. lung tissue damage. Our proposal is highly significant to human health, as it has great potential to
identify therapeutic targets for alleviating IAV immunopathology-associated mortality and morbidity.
流感病毒是快速突变的RNA病毒,并且是每年约10亿人死亡的病原体。
呼吸道病毒感染和全球50万人死亡。流感相关死亡通常可归因于
病毒性或细菌性肺炎(继发性细菌感染);过度炎症导致急性
呼吸窘迫综合征;以及严重的肺免疫病理学,导致缺氧和多器官衰竭。
流感病毒具有显著的大流行潜力,季节性流行给人类带来负担,
病毒对所有可用的治疗方案都产生了抗药性。许多重点放在体液
疫苗的作用是增强对流感的免疫应答,因为中和抗体是所需的疫苗结果。但是,B细胞-
缺乏T细胞的小鼠和患有高IgM综合征的人清除流感病毒感染,而T细胞缺乏的小鼠
不要。因此,不依赖于B细胞的机制可防止流感病毒相关死亡。但
对流感病毒感染的免疫应答仍然知之甚少,
增强抗病毒免疫应答同时防止有害的免疫病理学仍有待开发。
为了弥补这一知识缺口,我们最近获得了新的令人信服的证据,
(IAV)感染触发肺肥大细胞(MC)产生抗炎细胞因子IL-10(MC-IL-10)。在野外-
型(WT)和T-和B-细胞缺陷型(Rag 1-KO)小鼠,IAV/MC-IL-10诱导IL-10受体的表达
(IL-10 R)和程序性细胞死亡配体1(PD-L1)对自然杀伤(NK)细胞的作用。特别是,在Rag 1-KO小鼠中,
其中NK细胞是唯一的抗病毒淋巴细胞,PD-L1阻断,但不阻断PD-1、PD-L2或CD 80,
显著降低了IAV相关的致死率。IAV/MC-IL 10/NK-PD-L1通路在人类中也是保守的,
体外最少:人肺组织来源的单原代细胞悬液或完整人肺的IAV感染
组织切片引发MC-IL-10和NK细胞表达的IL-10 R和PD-L1。在小鼠和人类中,T细胞也
在IAV感染后上调IL-10 R、PD-1和PD-L1。此外,IAV感染的IL-10-KO/Rag-WT小鼠,
其NK和T细胞不上调IL-10 R、PD-1、PD-L1或PD-L2,以及IAV感染的WT小鼠,其中
PD-L1被阻断,在IAV清除后发生延长的免疫浸润和免疫病理学。我们的研究结果
都是新奇而令人惊讶的。PD/PD-L通路的诱导通常与淋巴细胞
在癌症或慢性感染中耗尽(通过T细胞表达的PD-1),而不是调节淋巴细胞
对急性病毒性疾病的反应。我们假设流感病毒诱导的MC-IL-10平衡
通过NK细胞中的PDL 1信号传导和PD-1和/或
T细胞中的PD-L1信号传导。我们提出了IAV/MC/IL-10/PD-L1介导的NK细胞的作用机制
和IAV/MC/IL-10/PD-1和/或PD-L1介导的T细胞调节以及每种途径对病毒感染的贡献
清除率与肺组织损伤。我们的建议对人类健康具有重要意义,因为它具有巨大的潜力,
鉴定用于减轻IAV免疫病理学相关死亡率和发病率的治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Silke Paust其他文献
Silke Paust的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Silke Paust', 18)}}的其他基金
Novel mechanisms regulating immunity to respiratory virus infection
调节呼吸道病毒感染免疫力的新机制
- 批准号:
10931141 - 财政年份:2023
- 资助金额:
-- - 项目类别:
How antigen exposure shapes the subsequent NK cell response to HIV
抗原暴露如何影响随后的 NK 细胞对 HIV 的反应
- 批准号:
10924725 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Control of HIV-induced MDSC expansion and immunosuppression by cytotoxic lymphocytes
细胞毒性淋巴细胞控制 HIV 诱导的 MDSC 扩增和免疫抑制
- 批准号:
10559918 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Control of HIV-induced MDSC expansion and immunosuppression by cytotoxic lymphocytes
细胞毒性淋巴细胞控制 HIV 诱导的 MDSC 扩增和免疫抑制
- 批准号:
10674910 - 财政年份:2022
- 资助金额:
-- - 项目类别:
How antigen exposure shapes the subsequent NK cell response to HIV
抗原暴露如何影响随后的 NK 细胞对 HIV 的反应
- 批准号:
10561720 - 财政年份:2021
- 资助金额:
-- - 项目类别:
How antigen exposure shapes the subsequent NK cell response to HIV
抗原暴露如何影响随后的 NK 细胞对 HIV 的反应
- 批准号:
10374918 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mechanisms of Protection of Universal Therapeutic Antibodies to Influenza A
甲型流感通用治疗抗体的保护机制
- 批准号:
10078587 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Harnessing NK Memory To Protect Against HIV Infection
利用 NK 记忆来预防 HIV 感染
- 批准号:
8996549 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Harnessing NK Memory To Protect Against HIV Infection
利用 NK 记忆来预防 HIV 感染
- 批准号:
9204387 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Harnessing NK Memory To Protect Against HIV Infection
利用 NK 记忆来预防 HIV 感染
- 批准号:
9430685 - 财政年份:2015
- 资助金额:
-- - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
-- - 项目类别: